Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure.
acute-on-chronic liver failure
endotoxin activity
rifaximin
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
14 May 2020
14 May 2020
Historique:
received:
17
04
2020
revised:
06
05
2020
accepted:
12
05
2020
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
20
5
2020
Statut:
epublish
Résumé
Acute-on-chronic liver failure (ACLF) leads to systematic inflammatory response syndrome and multiple organ failure. This study investigated the relationship between endotoxin (Et) and ACLF with the aim of determining whether Et activity (EA) is useful as a predictive biomarker of ACLF development and whether rifaximin treatment decreased the risk of ACLF development. Two hundred forty-nine patients with liver cirrhosis were enrolled in this study. Et concentration was determined in the whole blood by a semiquantitative EA assay. Predictive factors of ACLF development and the risk of ACLF development with and without rifaximin treatment were identified by univariate and multivariate analysis using Fine and Gray's proportional subhazards model. EA level was higher in Child-Pugh class B than in class A patients, and class B patients had an increased risk of ACLF development compared with class A patients. Multivariate analysis showed that EA level was a predictive factor independently associated with ACLF development. Rifaximin decreased EA level and the risk of ACLF development in Child-Pugh class B patients. Et levels were associated with functional liver capacity and were predictive of ACLF development in cirrhotic patients. Rifaximin decreased Et level and the risk of ACLF development in advanced cirrhotic patients.
Identifiants
pubmed: 32422875
pii: jcm9051467
doi: 10.3390/jcm9051467
pmc: PMC7290888
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Cell Mol Med. 2013 Jun;17(6):800-14
pubmed: 23635013
J Clin Med. 2020 Feb 19;9(2):
pubmed: 32092979
J Gastroenterol. 2016 Jul;51(7):629-50
pubmed: 27246107
Infect Immun. 2014 Sep;82(9):3678-86
pubmed: 24935972
Lancet. 1999 Jan 9;353(9147):139-42
pubmed: 10023916
Eur J Gastroenterol Hepatol. 2018 Feb;30(2):130-135
pubmed: 29200007
Nat Rev Gastroenterol Hepatol. 2016 Mar;13(3):131-49
pubmed: 26837712
World J Gastroenterol. 2002 Dec;8(6):961-5
pubmed: 12439906
Gastroenterol Res Pract. 2016;2016:9671327
pubmed: 27980536
J Gastroenterol Hepatol. 2013 Mar;28(3):450-5
pubmed: 23216382
Biomed Rep. 2017 Sep;7(3):277-285
pubmed: 28894574
Hepatol Res. 2019 Feb;49(2):232-238
pubmed: 30198141
Liver Int. 2018 May;38(5):875-884
pubmed: 29105936
Hepatol Commun. 2018 Sep 21;2(11):1331-1343
pubmed: 30411080
Gastroenterology. 2018 Nov;155(5):1564-1577
pubmed: 30055171
Antibiotics (Basel). 2020 Mar 29;9(4):
pubmed: 32235367
Hepatol Res. 2018 Mar;48(4):303-312
pubmed: 29341357
J Gastroenterol. 2020 May;55(5):533-542
pubmed: 31832759
Visc Med. 2018 Aug;34(4):270-275
pubmed: 30345284
J Inflamm (Lond). 2013 Mar 06;10(1):8
pubmed: 23510603
Hepatology. 1989 Nov;10(5):788-94
pubmed: 2807157
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Hepatol Res. 2018 Mar;48(4):219-224
pubmed: 29361652
Aliment Pharmacol Ther. 2017 Nov;46(9):845-855
pubmed: 28836723
World J Gastroenterol. 2017 Dec 21;23(47):8355-8366
pubmed: 29307995
J Hepatol. 2015 Feb;62(2):332-9
pubmed: 25457205
Nat Rev Immunol. 2009 Nov;9(11):799-809
pubmed: 19855405
Hepatol Res. 2018 Feb;48(3):E52-E60
pubmed: 28628948
Crit Care. 2012 Dec 03;16(6):248
pubmed: 23206992
J Clin Med. 2019 Aug 29;8(9):
pubmed: 31470579
Front Pharmacol. 2016 May 09;7:120
pubmed: 27242527
J Hepatobiliary Pancreat Sci. 2014 Feb;21(2):120-7
pubmed: 23798326
Gut. 1979 Mar;20(3):205-10
pubmed: 437553
Blood Purif. 2016;42(4):294-300
pubmed: 27577953